BIODESIX INC (BDSX)

Company Profile

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 217 full-time employees. The company went IPO on 2020-10-28. The firm develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Company Info

BIODESIX INC

919 West Dillon Road

Louisville COLORADO

P: 13034170500

Employees: 217

Website: https://www.biodesix.com/